Poland· PL-100478486

Bosutinib Stada

A bosutinib product containing bosutinibum, registered in Poland by STADA Arzneimittel AG. The same ATC class is registered in 15 of our 19 countries.

ATC L01EA04

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about bosutinibumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Bosutinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EA04 (bosutinib), each read from that country’s own register.

This record: Poland, from URPL (Poland)
8 of them publish a price we can compare per daily dose

Search bosutinib products by name

Bosutinib · ATC L01EA04

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bosutinib costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Bosutinib · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

CH Switzerland$65.58

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Bosutinibum
Manufacturer: STADA Arzneimittel AG
Country: Poland (PL)
ATC code: L01EA04
ATC class: Bosutinib
Defined daily dose: 0.4 g, O
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 2

gtin
05909991538507
gtin
05909991538514

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

469 interactions on record for bosutinib.

Graded by severity as the source publishes them — 159 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check bosutinib against other medicines How interaction checks work

Bosutinib · interactions on record

469 records

159 severe
307 moderate
3 minor

Most severe, free to view

PapaverineA03AD01severe
CisaprideA03FA02severe
DolasetronA04AA04severe
AprepitantA04AD12severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bosutinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bosutinib products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

Austria · Bosutinib Sandoz, Bosutinib Teva
Belgium · Bosutinib Eg, Bosutinib Eg (Eurogeneric)
Bulgaria · Босутиниб Msn, Босутиниб Зентива
Czechia · Bosutinib Msn, Bosutinib Teva
Germany · Bosutinib, Bosutinib Al
Denmark · Bosutinib Newbury, Bosutinib Sandoz
Estonia · Bosutinib Msn
Spain · Bosutinib, Bosutinib Vivanta
Finland · Bosutinib Stada
France · Bosutinib Biogaran, Bosutinib Eg Labo
United Kingdom (Northern Ireland) · Bosutinib Dr. Reddy’s, Bosutinib Stada
Croatia · Bosutinib Msn, Bosutinib Onkogen
Hungary · Bosutinib Onkogen, Bosutinib Sandoz
Ireland · Bosutinib Clonmel, Bosutinib Rowex
Iceland · Bosulif, Bosutinib Beta
Italy · Bosutinib Dr. Reddys, Bosutinib Eg
Liechtenstein · Bosulif
Lithuania · Bosutinib Msn
Luxembourg · Bosutinib Eg
Latvia · Bosutinib Msn
Malta · Bosutinib, Bosutinib Lotus
Netherlands · Bosutinib, Bosutinib Cf
Norway · Bosulif, Bosutinib Newbury
Portugal · Bosutinib Teva
Romania · Bosutinib Teva
Sweden · Bosutinib Newbury, Bosutinib Sandoz
Slovenia · Bosutinib Msn

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/bc27d980-0f8c-4ca5-a0b3-96608ea01ab3
GET /v1/drugs/bc27d980-0f8c-4ca5-a0b3-96608ea01ab3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "400 mg",
  "packaging": "05909991538507 ¦ Rpz ¦ 154425\n28 tabl.\n05909991538514 ¦ Rpz ¦ 154426\n112 tabl.",
  "substance": "Bosutinibum 400 mg",
  "common_name": "Bosutinibum",
  "pl_product_id": "100478486",
  "pozwolenie_nr": "28399",
  "auth_procedure": "DCP",
  "authorisation_validity": "2029-05-10"
}

API reference MCP server Plans

See everything about bosutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console